Phase 1 trial of targeted alpha-particle immunotherapy with actinium-225 ((225)Ac)-lintuzumab (Anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML) Meeting Abstract
| Authors: | Jurcic, J. G.; Ravandi, F.; Pagel, J. M.; Park, J. H.; Smith, B. D.; Levy, M. Y.; Estey, E. H.; Perl, A. E.; Kantarjian, H.; Earle, D.; Cicic, D.; Scheinberg, D. A. |
| Abstract Title: | Phase 1 trial of targeted alpha-particle immunotherapy with actinium-225 ((225)Ac)-lintuzumab (Anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML) |
| Meeting Title: | 57th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 126 |
| Issue: | 23 |
| Meeting Dates: | 2015 Dec 5-8 |
| Meeting Location: | Orlando, FL |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2015-12-03 |
| Language: | English |
| ACCESSION: | WOS:000368021800051 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood.V126.23.3794.3794 |
| Notes: | Meeting Abstract: 3794 -- 57th Annual Meeting of the American-Society-of-Hematology -- DEC 05-08, 2015 -- Orlando, FL -- Source: Wos |
